Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.11Last Year’s EPS
0.07Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -6.58%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call indicates a strong performance with significant revenue growth, particularly in the Decipher and Afirma tests, and positive developments in upcoming product launches. However, challenges with the SAS subsidiary and some revenue impacts due to prior period collections and tariffs present potential hurdles.Company Guidance
In the recent Q1 2025 financial results call, Veracyte provided guidance that highlighted several key metrics and strategic initiatives. The company reported total revenue of $114.5 million, marking an 18% year-over-year increase. Testing revenue grew 19% year-over-year, with double-digit volume growth in their Decipher and Afirma tests, at 37% and 10%, respectively. The adjusted EBITDA margin was 21.6%, surpassing expectations, and the company ended the quarter with $287 million in cash and short-term investments. For 2025, Veracyte reiterated its testing revenue guidance of $470-480 million and raised its adjusted EBITDA margin guidance to 22.5% from 21.6%. The company is focused on expanding its testing portfolio, including the launch of Decipher Prostate for metastatic populations and a new Prosigna LDT for the U.S. breast cancer market. They also emphasized progress in their MRD platform, targeting a commercial launch in the first half of 2026, and highlighted their commitment to international expansion despite operational changes in their French subsidiary.Strong Revenue Growth
Veracyte reported Q1 2025 revenue of $114.5 million, an 18% year-over-year increase, driven by testing revenue growth of 19%.
Decipher's Impressive Performance
Decipher volume grew 37% year-over-year with revenue growth of 33%. The test is now expanding into the metastatic prostate cancer market.
Afirma Volume Growth
Afirma saw a 10% increase in test volume year-over-year, indicating strong demand and market penetration.
Positive Adjusted EBITDA Margin
The company achieved an adjusted EBITDA margin of 21.6%, exceeding expectations.
Advancement in New Product Launches
Veracyte is set to launch Prosigna as an LDT for the U.S. breast cancer market and progressing with its MRD platform for muscle invasive bladder cancer, aiming for a 2026 launch.
---
VCYT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VCYT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $30.84 | $31.21 | +1.20% |
Feb 24, 2025 | $39.36 | $33.46 | -14.99% |
Nov 06, 2024 | $36.59 | $37.34 | +2.05% |
Aug 06, 2024 | $21.82 | $27.05 | +23.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Veracyte (VCYT) report earnings?
Veracyte (VCYT) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Veracyte (VCYT) earnings time?
Veracyte (VCYT) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VCYT EPS forecast?
VCYT EPS forecast for the fiscal quarter 2025 (Q2) is 0.11.
---